Form 4: Amgen SVP & CCO Nancy Grygiel Reports Changes in Beneficial Ownership

Nancy Grygiel, SVP & CCO of Amgen, reports the disposition of 106 shares of common stock to cover tax obligations related to vesting Restricted Stock Units (RSUs) and dividend equivalents, while also holding 12,114 shares directly and 99.9653 shares indirectly through a 401(k) plan.

Summary

• On April 30, 2024, Nancy Grygiel, SVP & CCO of Amgen, reported a transaction involving Amgen's common stock.
• 106 shares were disposed of at a price of $276.38 to cover tax obligations.
• Following the transaction, Ms. Grygiel directly owns 12,114 shares of Amgen common stock.
• She also indirectly owns 99.9653 shares through the company's 401(k) plan.
• The directly held shares include Restricted Stock Units (RSUs) vesting at various dates in the future.
• These RSUs will be paid out in shares of Amgen's common stock on a one-to-one basis.
• The directly held shares also include 457 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing and does not inherently convey positive or negative sentiment. It simply reports transactions related to executive stock ownership.

Future Outlook

The document does not contain specific forward-looking statements regarding the company's future performance, but it does detail the vesting schedule for Ms. Grygiel's RSUs.

Industry Context

This filing is a routine disclosure related to executive compensation and stock ownership, common in publicly traded companies like Amgen. It provides transparency into the holdings and transactions of key personnel.

Comparison to Industry Standards

• Executive compensation packages including RSUs are standard practice among large pharmaceutical companies such as Pfizer, Johnson & Johnson, and Merck.
• The vesting schedules and dividend equivalent programs are also common features designed to align executive interests with long-term shareholder value.
• Form 4 filings are a standard regulatory requirement for insiders of publicly traded companies in the US, ensuring transparency in their trading activities.

Stakeholder Impact

• The filing provides transparency to shareholders regarding executive stock ownership.
• The transactions have a minimal direct impact on employees, customers, suppliers, or creditors.

Key Dates